Video

Dr. Parker on next steps with mpMRI in prostate cancer

Author(s):

Urology Times staff

William P. Parker, MD, shares his expectations for the future of multiparametric MRI (mpMRI) in prostate cancer and where micro-ultrasound may fit alongside mpMRI in the paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.

Related Videos
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
February 21st 2025

Piflufolastat F 18 yields high detection rate even at low PSA levels for prostate cancer

Benjamin P. Saylor
Total detection rate was 36% (13/36) in the ultra-low PSA group and 51% (47/93) in the low-PSA group.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC
February 19th 2025

FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC

Hannah Clarke
The designation is supported by preliminary data from the ongoing phase 1/2a SECuRE trial.
Dr. Bristol Whiles discusses her experience as a urology resident
July 25th 2022

Dr. Bristol Whiles discusses her experience as a urology resident

Kansas University Department of Urology
On this podcast, Bristol Whiles, MD, discusses her urology residency experience at the Kansas University School of Medicine Department of Urology.
Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer
February 11th 2025

Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer

Hannah Clarke
Illuccix has been previously approved in the US, Australia, Canada, and Europe.
Key FDA decisions urologists can expect in the first half of 2025
January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke
Check out the key regulatory decisions set to happen early this year.
© 2025 MJH Life Sciences

All rights reserved.